CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer cellular immunotherapies derived from umbilical cord blood

(2017) Katalin Balassa et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy

(2017) Lisa Rosenbaum   NEW ENGLAND JOURNAL OF MEDICINE

Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children

(2017) Jeffrey S. Upperman et al.   Pediatric Critical Care Medicine

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

(2017) Dina Schneider et al.   Journal for ImmunoTherapy of Cancer

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives

(2017) J. Gauthier et al.   Current Research in Translational Medicine

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

(2016) Elad Jacoby et al.   Nature Communications

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

Trial of novel leukaemia drug is stopped for second time after two more deaths

(2016) Nigel Hawkes   BMJ-British Medical Journal

Trial of novel leukaemia drug is stopped for second time after two more deaths

(2016) Nigel Hawkes   BMJ-British Medical Journal

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

(2015) M. A. Pulsipher et al.   BLOOD

Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

(2015) M A Pulsipher et al.   BONE MARROW TRANSPLANTATION

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations

(2015) Drew C. Deniger et al.   PLoS One

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Childhood and adolescent cancer statistics, 2014

(2014) Elizabeth Ward et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

(2014) Yao Wang et al.   CLINICAL IMMUNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States

(2014) Dianne Pulte et al.   PLoS One

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Relapsed childhood acute lymphoblastic leukaemia

(2013) Deepa Bhojwani et al.   LANCET ONCOLOGY

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

How I treat relapsed childhood acute lymphoblastic leukemia

(2012) F. Locatelli et al.   BLOOD

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

(2011) H. Trottestam et al.   BLOOD

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

(2010) Renier Brentjens et al.   MOLECULAR THERAPY

Monoclonal antibody-induced cytokine-release syndrome

(2009) Peter J Bugelski et al.   Expert Review of Clinical Immunology

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA